Related Experiment Video
Updated: Aug 16, 2026

An In Vitro Assay to Detect tRNA-Isopentenyl Transferase Activity
Published on: October 8, 2018
FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain
Objective:
The chromosomal regions containing the two putative tumour suppressors, fragile histidine triad gene (FHIT) and tumour suppressor gene 101 (TSG101), are deleted frequently in thyroid tumours. We therefore analysed FHIT and TSG101 transcripts in a group of advanced thyroid tumours to establish their role in thyroid tumorigenesis.
Design:
Retrospective analysis of FHIT and TSG101 mRNA transcripts and genomic DNA from cryo-preserved thyroid tumours. TP53, previously shown at the genomic level not to be mutated in this cohort of tumours, served as a control.
Patients:
We analysed nine follicular thyroid carcinomas (FTC), six papillary thyroid carcinomas and six follicular adenomas (FA) and histologically normal thyroid tissue from four of the FA patients.
Measurements:
Single stage and nested reverse transcription polymerase chain reaction (RT-PCR) products of FHIT, TSG101, and TP53 were analysed by agarose or polyacrylamide gel electrophoresis and sequenced. Genomic DNA was also analysed by polymerase chain reaction and sequencing (FHIT) or by Southern blotting (TSG101). Clinical data were correlated with the results of the mutation analysis.
Results:
Truncated FHIT transcripts were observed frequently alongside full length transcripts with nested RT-PCR, most often in FTC, while single stage RT-PCR revealed only normal length transcripts in all tumours. Similar results were obtained for TP53, while abnormal TSG101 transcripts were detectable by single stage RT-PCR. Sequence analysis of the truncated FHIT and TSG101 transcripts revealed mainly exon skipping and alternate RNA processing events. Only a single point mutation (of TSG101) was found. Southern blotting for the TSG101 gene, and PCR amplification and sequencing of the FHIT gene showed no evidence of genomic abnormalities in either case, and there was no evidence of splice site mutations in the FHIT gene, suggesting that the truncated transcripts result from altered RNA processing. There was no relationship between tumour stage, grade or survival and the presence of FHIT or TSG101 abnormalities.
Conclusions:
Truncated FHIT and TSG101 transcripts in thyroid tumours reflect alternate mRNA splicing events, rather than genomic deletions. Such abnormal RNA processing seems to be common and widespread in thyroid neoplasms, as similar results were obtained by analysis of transcripts of TP53, which we had previously shown not to be mutated in these specimens. Although a pathogenetic role for these aberrant transcripts remains possible, no correlation was found with stage, histological grade or outcome in this small group of advanced thyroid malignancies. Relaxation of mRNA splice control appears to be a feature of follicular cell-derived thyroid neoplasms.
Insights
Altered RNA processing, not gene deletion, causes abnormal FHIT and TSG101 transcripts in thyroid tumors. This widespread splicing defect in thyroid neoplasms may indicate a common feature of follicular cell-derived tumors.
Area of Science:
- Molecular oncology
- Thyroid cancer research
- Gene expression analysis
Background:
- Frequent deletions of tumor suppressor genes, fragile histidine triad gene (FHIT) and tumor suppressor gene 101 (TSG101), are observed in thyroid tumors.
- The precise role of FHIT and TSG101 in thyroid tumorigenesis requires further investigation.
Purpose of the Study:
- To analyze FHIT and TSG101 transcripts in advanced thyroid tumors.
- To determine the role of FHIT and TSG101 in thyroid cancer development.
Main Methods:
- Retrospective analysis of FHIT, TSG101, and TP53 mRNA transcripts and genomic DNA from cryopreserved thyroid tumors.
- Utilized reverse transcription polymerase chain reaction (RT-PCR), sequencing, and Southern blotting.
- Analyzed nine follicular thyroid carcinomas, six papillary thyroid carcinomas, six follicular adenomas, and normal thyroid tissue.
Main Results:
- Truncated FHIT transcripts were frequently observed, particularly in follicular thyroid carcinomas, alongside full-length transcripts.
- Abnormal TSG101 transcripts were detected, primarily due to exon skipping and alternative RNA processing, not genomic mutations.
- No correlation was found between tumor stage, grade, or survival and the presence of FHIT or TSG101 abnormalities.
Conclusions:
- Truncated FHIT and TSG101 transcripts in thyroid tumors result from alternative mRNA splicing, not genomic deletions.
- Altered RNA processing appears common in thyroid neoplasms, suggesting a potential feature of follicular cell-derived tumors.
- While a pathogenetic role for aberrant transcripts is possible, no direct correlation with clinical outcomes was established in this cohort.
More Related Videos
Related Concept Videos
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Non-LTR Retrotransposons
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Leaky Scanning
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

